Current Strategies and Emerging Paradigms of Immunotherapy in Microsatellite Stable Colorectal Cancer: A Review Article
Clinical Drug Investigation · 2026-07 · 46 (7) · 701-720
DOI: 10.1007/s40261-025-01520-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Drug Investigation, online erschienen am 29.05.2026. Verfasst von Lu-Ying Zhan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, 158 Sha…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit nennt 112 Literaturangaben.
Abstract (Originalsprache)
Immunotherapy, especially through the innovative use of immune checkpoint inhibitors (ICIs), has rapidly become an essential component in both first-line and subsequent treatment strategies for cancers that exhibit DNA mismatch repair defects or display high microsatellite instability (dMMR/MSI-H). These therapies harness the power of the immune system to target and destroy cancer cells more effectively. However, the application of ICIs in patients diagnosed with microsatellite stable (MSS) colorectal cancer presents considerable hurdles. These challenges largely arise from the inherent tumor heterogeneity and the complex immune landscape characteristic of the tumor microenvironment. It is crucial to highlight that numerous clinical trials are actively underway, aimed at deepening our understanding of the mechanisms at play and paving the way for future advancements in this arena. This article endeavors to provide an extensive review of the current literature surrounding the application of ICIs in MSS colorectal cancer. We aim to deliver a thorough overview of the present state of immunotherapy for this subset of colorectal cancer, beginning with an exploration of various combination therapy strategies that enhance immune responses. Moreover, we will investigate several adverse prognostic factors that affect MSS colorectal cancer patients undergoing immunotherapy. A particular focus will be placed on the detrimental effects of liver metastasis and the influence of local treatment modalities for liver metastasis on patient clinical outcomes. This narrative review compiles current knowledge to serve as a reference point for identifying potential patient populations that could benefit from immunotherapy in the future, ultimately striving for improved therapeutic approaches and patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, 158 Shangtang Road, Hangzhou, 310014, Zhejiang, People's Republic of China.
- The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310000, Zhejiang, People's Republic of China.
- Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, 158 Shangtang Road, Hangzhou, 310014, Zhejiang, People's Republic of China. c…
- Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, 158 Shangtang Road, Hangzhou, 310014, Zhejiang, People's Republic of China. y…
Zitieren
APA
Zhan, L. Y., Chen, Z. L., & Yang, L. (2026). Current Strategies and Emerging Paradigms of Immunotherapy in Microsatellite Stable Colorectal Cancer: A Review Article. Clinical Drug Investigation, 46(7), 701-720. https://doi.org/10.1007/s40261-025-01520-0
Vancouver
Zhan LY, Chen ZL, Yang L. Current Strategies and Emerging Paradigms of Immunotherapy in Microsatellite Stable Colorectal Cancer: A Review Article. Clinical Drug Investigation. 2026;46(7):701-720. doi:10.1007/s40261-025-01520-0
BibTeX
@article{Zhan2026,
author = {Zhan, Lu-Ying and Chen, Zhe-Ling and Yang, Liu},
title = {Current Strategies and Emerging Paradigms of Immunotherapy in Microsatellite Stable Colorectal Cancer: A Review Article},
journal = {Clinical Drug Investigation},
year = {2026},
volume = {46},
number = {7},
pages = {701--720},
doi = {10.1007/s40261-025-01520-0}
}
EUVIMED